Vanda Pharmaceuticals
As of the edition of 20 October 2026, Vanda Pharmaceuticals runs 11 drugs, 4 of them marketed; it is on route A at 0 targets and on route B at 5 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 4 |
| Went quiet | 1 |
| Stopped | 1 |
| Status not established | 1 |
| Total | 11 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Tasimelteon | Ends 2035 (patent) | 2 |
| Iloperidone | Ends 2027 (exclusivity) | 1 |
| Tradipitant | Ends 2030 (exclusivity) | 1 |
| Ponesimod | Ends 2032 (patent) | 2 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 5 targets.
All 5 rows on route A or B
In the product5 company-target rows on route A or B; 2 are not shown here, and no score is.
See all 5 targets where Vanda Pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Mental health: 23 trials led
- Nervous system: 16 trials led
- Skin and connective tissue: 14 trials led